The increasing number of breast cancer cases all over the world is anticipated to boost the global breast cancer therapeutics market at promising rates, finds Fortune Business Insights in a new study. The study is titled, “Breast Cancer Therapeutics Market: Global Market Analysis, Insights, and Forecasts”. According to the report, the global market, which stood at US$ 17,868.8 Mn in 2018, will reach US$ 38,573.5 Mn by the end of 2026. If these figures prove true, the global market will rise at a CAGR of 10.2% between 2018 and 2026.
According to the World Health Organization, in 2018, an approximate of 627,000 women, which is tantamount to 15% of all cancer deaths worldwide, succumbed to breast cancer. The rising incidence of breast cancer is one of the chief drivers of the global breast cancer therapeutics market.
Browse Complete Report Details @ https://www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163
Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
• Genentech (F. Hoffmann-La Roche Ltd)
• Eli Lilly and Company
• Celgene Corporation
• Pfizer Inc.
• Eisai Co. Ltd.
• Kyowa Kirin
• Bristol Myers Squibb
• Mayne Pharma Group Limited
• Novartis AG
• Valeant Pharmaceuticals
“High Intake of Oral Contraceptives Among Women, Boosting Market”
Breast cancer can develop due to reasons such as reduced breast feeding, rise in age of childbearing, undergoing estrogen modifying drug treatments and high intake of oral contraceptive pills. The increase in the number of women complaining of such problems and the successive rise in the number of breast cancer cases are factors boosting the Breast Cancer Therapeutics Market during the forecast period.
Another factor creating lucrative growth opportunities for breast cancer therapies is the increasing number of obese women. With change in lifestyle and unhealthy food habits, the rate of obesity is increasing by the day. Obesity further causes various health problems such as cardiovascular disorders, gall bladder diseases, diabetes, breathing problems, and breast cancer among others.
However, some breast cancer drugs may have serious side effects and this may act as a hindrance to the market. Besides this, countries that lack of awareness may restrict expansion of the market. Also social taboos prevalent in these countries may act as major deterrents to Breast Cancer Therapeutics Market growth.
“North America to Remain Dominant on Account of Presence of Skilled Professionals”
The breast cancer treatment market in North America is currently leading the global landscape, supported by the presence of a well-established healthcare infrastructure and rising uptake of advanced facilities in the region. In 2018, North America generated a revenue of US$ 8,033.8 Mn, because of the increasing prevalence of breast cancer in the region. In addition to this, the region boasts presence of several leading market players and skilled professionals.
Besides this, governments of developed nations such as Canada and the U.S. are providing health insurance for cancer diagnostics. Spurred by these factors the breast cancer therapeutics market is likely to flourish in North America to emerge dominant.
“Looming Patent Expiries Fuels Demand for Generic Drugs”
The global breast cancer therapeutics market is likely to witness the prevalence of high competition. According to the report, Genentech, Inc. (F. Hoffmann-La Roche Ltd) held the dominant share in the market in 2018. Growth of the company is backed by its diverse product portfolio in targeted and chemotherapy segment.
Order Full Report @ https://www.fortunebusinessinsights.com/checkout-page/100163
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• North America (U.S. and Canada)
• Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia Pacific (China, India, Japan, Australia, South East Asia and Rest of Asia Pacific)
• Latin America (Brazil, Mexico and Rest of Latin America
• Middle East & Africa (GCC, South Africa and Rest of Middle East & Africa)
Table of Contents for Breast Cancer Therapeutics Market:
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Prevalence of Breast Cancer Therapeutics by Key Countries
4.2 Regulatory Scenario by Key Regions
4.3 Key Industry Developments
4.4 Overview of Current Advances in R&D for Breast Cancer Therapeutics
More Trending Topics from Future Business Insights:
The Revenue Cycle Management (RCM) Market to Reach US$ 216.9 Mn by 2026; Increasing Patient Pool to Boost Growth, says Fortune Business Insights
The ePharmacy Market to Reach US$ 177,794.9 Mn by 2026; Expansion of Online Retailing to Boost Growth, says Fortune Business Insights